ReviewCureus2025
How Important Is Vitamin D Supplementation in the Prevention of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD): An Evidence-Based Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vitamin D and Health Outcomes: State-of-the-Art Review of Triangulated Evidence and Ongoing Controversies.Current nutrition reports · 2026Review
- Lower Vitamin D During Acute Exacerbation Is Associated with Very Severe Chronic Obstructive Pulmonary Disease.Medicina (Kaunas, Lithuania) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review examines the efficacy of vitamin D supplementation in preventing exacerbations in patients with chronic obstructive pulmonary disease (COPD), a major global contributor to morbidity and mortality. Exacerbations, often caused by infections, significantly worsen outcomes and elevate healthcare costs. Given its immunomodulatory properties, vitamin D has been hypothesized to reduce exacerbations, particularly in populations with vitamin D deficiency. A systematic search of multiple databases was performed in February 2024 and evidence was synthesized from four systematic reviews with meta-analyses and one recent randomized controlled trial. Findings indicate that vitamin D supplementation does not generally reduce exacerbation rates in COPD patients. However, in patients with baseline 25-hydroxyvitamin D (25(OH)D) serum levels below 10 ng/mL, one meta-analysis reported a significant (p=0.006) reduction in moderate-to-severe exacerbations following supplementation. Variability in study designs, dosages, and follow-up durations limit the generalizability of these findings. Nevertheless, clinical guidelines recommend screening and supplementing vitamin D in COPD patients, particularly those with severe deficiency. Clinicians should consider the low cost and risk of vitamin D supplementation and its potential benefits in reducing exacerbations in such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.